Sanofi has announced a partnership with Biovac for the local production of inactivated polio vaccine (IPV) in Africa, to meet the potential needs of more than 40 African countries.

The French healthcare giant explains that this partnership supports the ambition of the African Centers for Disease Control and Prevention to have 60% of locally-administered vaccines produced in Africa by 2040.

Sanofi will continue to produce IPV in bulk form, and Biovac, which will hold the marketing authorization, will be responsible for the final stages of formulation, filling, packaging and distribution to UNICEF.

Copyright (c) 2024 CercleFinance.com. All rights reserved.